Abstract
This double-blind, placebo-controlled, cross-over study was designed to compare the efficacy of orally administered slow-release mexiletine (SM) (360 mg 2 bid for 5 days) and long-acting dihydroquinidine (LD) (250 mg 2 bid for 5 days) in reducing ventricular premature beats (VPBs). The protocol was completed by 12 hospitalized patients. Entry was determined by the presence of more than 720 VPBs in 2 pre-trial 24 hours Holter monitorings. The study protocol was as follows: during the 1st, 3rd and 5th three-day periods, each patient received the placebo of both drugs on single blind condition; during the 2nd and 4th five-day periods, the patients were given on double blind condition SM or LD (double dummy technique) and placebo of the other drug according to a cross-over design. The 5 periods were consecutive; at the end of each period the patients underwent a 24 hours Holter monitoring. The absence of significant VPBs/hour changes during the run-in period and the 3 placebo periods (522 ± 168, 461 ± 182, 547 ± 180 respectively) confirmed the stability of the arrhythmia during the whole study. Compared to placebo, SM and LD reduced VPBs/hour to 353 ± 194 (p 70% was observed in 67% and 33% of cases with SM and LD, respectively. SM and LD also induced a reduction of couplets/24 hours from 127 ± 59 to 21 ± 11 (p
| Original language | English |
|---|---|
| Pages (from-to) | 999-1003 |
| Number of pages | 5 |
| Journal | Cardiologia |
| Volume | 32 |
| Issue number | 9 |
| Publication status | Published - 1987 |
Fingerprint
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Cite this
Slow-release mexiletine in the treatment of ventricular premature beats. Comparison with long-acting dihydroquinidine. / Accettura, D.; De Toma, L.; Mangini, S. G.; Lagioia, R.; Scrutinio, D.; Mastropasqua, F.; Caiati, C.; Rizzon, P.
In: Cardiologia, Vol. 32, No. 9, 1987, p. 999-1003.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Slow-release mexiletine in the treatment of ventricular premature beats. Comparison with long-acting dihydroquinidine
AU - Accettura, D.
AU - De Toma, L.
AU - Mangini, S. G.
AU - Lagioia, R.
AU - Scrutinio, D.
AU - Mastropasqua, F.
AU - Caiati, C.
AU - Rizzon, P.
PY - 1987
Y1 - 1987
N2 - This double-blind, placebo-controlled, cross-over study was designed to compare the efficacy of orally administered slow-release mexiletine (SM) (360 mg 2 bid for 5 days) and long-acting dihydroquinidine (LD) (250 mg 2 bid for 5 days) in reducing ventricular premature beats (VPBs). The protocol was completed by 12 hospitalized patients. Entry was determined by the presence of more than 720 VPBs in 2 pre-trial 24 hours Holter monitorings. The study protocol was as follows: during the 1st, 3rd and 5th three-day periods, each patient received the placebo of both drugs on single blind condition; during the 2nd and 4th five-day periods, the patients were given on double blind condition SM or LD (double dummy technique) and placebo of the other drug according to a cross-over design. The 5 periods were consecutive; at the end of each period the patients underwent a 24 hours Holter monitoring. The absence of significant VPBs/hour changes during the run-in period and the 3 placebo periods (522 ± 168, 461 ± 182, 547 ± 180 respectively) confirmed the stability of the arrhythmia during the whole study. Compared to placebo, SM and LD reduced VPBs/hour to 353 ± 194 (p 70% was observed in 67% and 33% of cases with SM and LD, respectively. SM and LD also induced a reduction of couplets/24 hours from 127 ± 59 to 21 ± 11 (p
AB - This double-blind, placebo-controlled, cross-over study was designed to compare the efficacy of orally administered slow-release mexiletine (SM) (360 mg 2 bid for 5 days) and long-acting dihydroquinidine (LD) (250 mg 2 bid for 5 days) in reducing ventricular premature beats (VPBs). The protocol was completed by 12 hospitalized patients. Entry was determined by the presence of more than 720 VPBs in 2 pre-trial 24 hours Holter monitorings. The study protocol was as follows: during the 1st, 3rd and 5th three-day periods, each patient received the placebo of both drugs on single blind condition; during the 2nd and 4th five-day periods, the patients were given on double blind condition SM or LD (double dummy technique) and placebo of the other drug according to a cross-over design. The 5 periods were consecutive; at the end of each period the patients underwent a 24 hours Holter monitoring. The absence of significant VPBs/hour changes during the run-in period and the 3 placebo periods (522 ± 168, 461 ± 182, 547 ± 180 respectively) confirmed the stability of the arrhythmia during the whole study. Compared to placebo, SM and LD reduced VPBs/hour to 353 ± 194 (p 70% was observed in 67% and 33% of cases with SM and LD, respectively. SM and LD also induced a reduction of couplets/24 hours from 127 ± 59 to 21 ± 11 (p
UR - http://www.scopus.com/inward/record.url?scp=0023413932&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023413932&partnerID=8YFLogxK
M3 - Article
C2 - 2446764
AN - SCOPUS:0023413932
VL - 32
SP - 999
EP - 1003
JO - Cardiologia (Rome, Italy)
JF - Cardiologia (Rome, Italy)
SN - 0393-1978
IS - 9
ER -